Physician profile
Leonid Bukhman
NPI 1144334699
$7,135.62
in general payments reported to CMS, 2019-2025
30 companies · $1,250 in 2025
The $1,250 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,587 · 2020: $1,094 · 2021: $1,175 · 2022: $568 · 2023: $797 · 2024: $664 · 2025: $1,250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,711.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,711.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,784.87 | 2019-2025 | Linzess, Creon, Qulipta |
| Lilly USA, LLC | $765.42 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $679.12 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $642.01 | 2019-2025 | Breztri, Farxiga |
| Amgen INC. | $487.15 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $336.30 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Allergan, INC. | $294.28 | 2019-2020 | |
| Horizon Therapeutics Plc | $280.84 | 2019-2022 | |
| Amarin Pharma, INC. | $277.61 | 2019-2022 | |
| Pfizer INC. | $263.77 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $216.31 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $156.46 | 2019-2025 | |
| Genzyme Corporation | $148.01 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.21 | 2019-2020 | |
| Gilead Sciences, INC. | $103.42 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $94.16 | 2021-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $78.94 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $68.76 | 2020-2021 | |
| Astellas Pharma US INC | $60.68 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $58.41 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $41.27 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $27.56 | 2025 | Zoryve |
| Ironwood Pharmaceuticals, INC | $26.82 | 2024 | |
| Endo Pharmaceuticals INC. | $25.00 | 2019 | |
| Nevro Corp. | $21.86 | 2022 | |
| Merck Sharp & Dohme LLC | $20.57 | 2020 | |
| Redhill Biopharma INC. | $19.18 | 2020 | |
| Alnylam Pharmaceuticals INC. | $18.64 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $16.79 | 2019 | |
| Smith+Nephew, INC. | $15.20 | 2023 | Collagenase Santyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonid Bukhman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.